Week of Nov 2 – Nov 8, 2026

Methanogenic consortia drive the anaerobic conversion of organic matter into methane and CO2 — central both to the global carbon cycle and to engineered biogas biotechnologies. Decoding their functional and taxonomic landscape has been limited by reference databases that under-represent bacteriophages and plasmids. CAnDi (Catalogue of Anaerobic Digestion) is a new database assembled to close that gap, giving reactor operators and metagenomics pipelines a purpose-built reference for the organisms, viruses and mobile elements that actually run a digester.

Anaerobic digestion can reduce antibiotic-resistance genes (ARGs) and mobile genetic elements (MGEs) during waste treatment, but evidence from full-scale plants is limited and the relative weight of operational versus physicochemical drivers is unresolved. This study profiled stage-resolved resistome and mobilome dynamics — substrate, digestate and post-digestion storage — across ten Swedish farm-scale AD plants (42 samples), combining high-throughput qPCR (ResistoMap) with absolute 16S rRNA gene quantification and amplicon sequencing.

Genome-centric metagenomics of synthetic AD systems fed five substrates (starch, glucose, butyrate, propionate-valerate, acetate) recovered 390 high-quality metagenome-assembled genomes — 64.36% of them potentially novel species. Substrate selected distinct functional consortia (e.g. Bifidobacterium enriched in starch hydrolysis), mapping the organisms behind each step of the degradation cascade.

The first comprehensive database of protein families in wastewater microbiomes, integrating 580 metagenomes, 132 metatranscriptomes and 1,709 reference genomes (504 / 129 / 1,151 after filtering) and cataloguing 3,887 non-redundant protein families. It gives wastewater surveillance a functional reference layer rather than just taxonomy.

Five parallel 10-L continuous stirred-tank reactors were inoculated from a full-scale agricultural biogas plant to test how faithfully lab-scale microbiology reproduces full-scale behaviour — and how long stabilisation takes. It quantifies a recurring blind spot in AD research: whether bench reactors are actually representative of the processes they stand in for.

Volatile fatty acid (VFA) accumulation limits anaerobic digestion of lignocellulosic biomass by acidifying the reactor and unbalancing microbial metabolism. Using Paulownia leaf litter as substrate, hydrogen nanobubble water (H2-NBW) raised cumulative methane yields by 26.4-34.5% over controls, accelerated VFA turnover, and remodelled transcriptional networks in integrated multi-omics analyses.

In situ biomethanation upgrades biogas by feeding H2 to convert CO2 into CH4 inside the digester, but elevated H2 partial pressure can disrupt syntrophic interactions. Two 3-L mesophilic CSTRs tested whether prior H2 exposure adapts the community; H2-adapted communities held up under rising organic loading rate.

Ammonia toxicity remains a major bottleneck for stable AD operation, and trace-element supplementation is an established countermeasure — used to activate methanogenesis-related enzymes, reshape the community and improve process efficiency. This study asks how different trace elements modulate the biosynthesis and release of N-acyl homoserine lactones (AHLs), and the downstream relief of ammonia inhibition during biomethanation.

Anaerobic digestion yields methane-rich biogas and ammonium-rich digestate, and converting both into single-cell protein (SCP) requires coordinated carbon and nitrogen use. In a membrane biofilm reactor, ammonium addition impaired nitrogen conversion and protein enrichment without eliminating methylotrophs, while acetate restored function — raising protein content to 61.25% and the apparent N-based SCP yield from 0.34 to 1.46 g SCP/g N.

Lactate-driven dark fermentation can improve hydrogen recovery in mixed-culture fermentation, but continuous two-stage configurations are under-explored. A two-stage system treating synthetic food waste ran 180 days at stable H2 production rates of 2.02-2.65 NL H2/L-d with high resilience after a major process disturbance; the lactate-producing stage accumulated up to 8.15 g/L of lactate while removing only 29% of the supplied carbohydrates.

Adding the mRNA-based individualised neoantigen vaccine intismeran autogene to pembrolizumab after surgery for melanoma reduced the risk of recurrence or death by 42% in the phase III INTerpath-0001 trial, presented at ESMO 2026 in Madrid (23-27 October). It is the first phase III win for an mRNA cancer vaccine — though the field is quick to note the mechanism behind the benefit is not yet clear.

Glioblastoma poorly induces spontaneous CD8+ T-cell responses, and preclinical vaccine work is limited by a lack of stringent models with defined endogenous antigens. This preprint identifies Gpr149 as an endogenous, vaccine-targetable antigen in the checkpoint-refractory SB28 mouse glioblastoma model and shows vaccination against it induces protective immunity in the brain.

HERVolution reports foundational data that rationally engineered HERV-K (human endogenous retrovirus K) antigens can break immune tolerance and train immune cells to target tumour cells — a direct dark-genome-antigen play, distinct from mutation-derived neoantigens. Company announcement / press release.

Humans and chimpanzees diverged in brain size, structure and cognition over 5-7 million years despite high conservation of protein-coding genes, and retroviral infections have left species-specific regulatory elements behind. Chimpanzees carry lineage-specific PTERV1 endogenous retroviruses absent in humans; epigenomic analysis of PTERV1 insertions in chimpanzee neural organoids found them heavily DNA-methylated, forming over 150 species-specific heterochromatic regions.

ECM rigidity stabilises the prolyl isomerase Pin1, which preserves heterochromatin organisation and nuclear-envelope integrity, thereby suppressing transposable-element activity and enabling immune evasion in breast cancer. Links mechanical tumour cues to dark-genome silencing — the inverse of the therapeutic strategy of releasing TE-derived antigens.

A review of how tumour immunoediting and immune escape reshape the neoantigen landscape, and why personalised neoantigen vaccines — despite robust induction of neoantigen-specific T cells — have yielded inconsistent clinical efficacy. Frames the selection pressure any vaccine design must overcome.

Linked a novel TLR2/6 agonist adjuvant (C-VAX, derived from the natural agonist UNE-C1) to a KRAS G12D neoantigen and evaluated the integrated vaccine in a KPC orthotopic pancreatic cancer model. Targets one of the most vaccine-refractory tumours and one of the most common driver mutations.

Constructed a pan-cancer landscape of intratumoral microbiota-derived epitopes from 1,190 samples across 24 cancer types, finding microbial epitopes differ from human ones in hydrophobicity, aliphatic index and stability, and that certain HLA-I alleles preferentially bind them. Microbiome-derived antigens as immunotherapy/prevention targets.

A fixed splice-junction vaccine panel needs junctions that recur across patients yet are absent from normal tissue — absence inferred from non-detection in finite references. Screening 1,263,305 junctions across 300 secreted, membrane and HCC-associated genes for 30% recurrence in 374 TCGA-LIHC tumours and absence in 50 matched normals and 251 GTEx liver samples, no junction met the pre-specified criteria: widely recurring junctions also occurred in normal tissue.

Nanovaccine design has explored size, shape, surface charge and targeting, but antigen density has remained under-examined. Fine-tuning the antigen ratio on an M13 phage capsid from about 6.0% to about 70.4% enhanced the anti-tumour CD8+ T-cell response, with the density-dependent effect then investigated further.

Trade coverage reports improved progression-free survival in the iNATURE trial of a personalised neoantigen vaccine combined with radiotherapy — a second individualised-vaccine readout published alongside the melanoma Phase III.

Newly posted phase 1 trial of a personalised 'TMV' vaccine — particles derived from each participant's own tumour — alone or with the PD-1 inhibitor toripalimab-tpzi, in recurrent head-and-neck squamous cell carcinoma planned for surgery. NCT07898124, sponsored by Metaclipse Therapeutics.

Trade coverage reports Geneos opening a phase 2 trial (IMPACT31) of a personalised DNA cancer vaccine aimed at preventing recurrence of liver cancer — the adjuvant, prevention-of-recurrence setting where vaccine programmes are concentrating.

The Boston Globe reports Moderna's shares fell even after data confirmed the Merck-partnered cancer vaccine met key endpoints in the melanoma trial — a market read on how the milestone was priced and received.

STAT's analysis argues the field's next contest is extending the vaccine's benefit beyond melanoma — the competitive question that appears once a first phase III result exists.

Biosphere raised US$21M to scale domestic chemical manufacturing — a gas-/precision-fermentation play adjacent to bioreactor bioprocessing.

A market forecast for bioreactor gas sparger assemblies to 2035, driven by single-use bioprocessing expansion — an instrumentation and consumables opportunity in bioreactor scale-up.